Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for ...

Walmart Pharmacies to offer weight-loss drug making obesity treatment more accessible for millions nationwide.

Wall Street rallied higher as investors digested upbeat earnings from big tech companies during the week. The Nasdaq gained 2 ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

el agonista del GLP-1 de Eli Lilly comercializado como Mounjaro para el tratamiento de la diabetes y Zepbound para la pérdida de peso, afecta los síntomas durante un período de 12 meses. «Se ha ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...